IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v34y2016i7d10.1007_s40273-016-0386-z.html
   My bibliography  Save this article

Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Author

Listed:
  • Hazel Squires

    (University of Sheffield)

  • Matt Stevenson

    (University of Sheffield)

  • Emma Simpson

    (University of Sheffield)

  • Rebecca Harvey

    (University of Sheffield)

  • John Stevens

    (University of Sheffield)

Abstract

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of trastuzumab emtansine (T-DM1) (Kadcyla®; Roche) to submit evidence of its clinical and cost-effectiveness for treating human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane. The School of Health and Related Research Technology Appraisal Group (ScHARR-TAG) at the University of Sheffield were the independent Evidence Review Group (ERG) who produced a critical review of the company’s submission to NICE. The ERG also independently searched for relevant evidence and modified the submitted decision analytic model to produce a revised estimate of cost-effectiveness and examine the impact of altering some of the key assumptions. The clinical effectiveness data were taken from two randomised controlled trials that reported a significant advantage in progression-free survival (PFS) for T-DM1 over lapatinib in combination with capecitabine (EMILIA trial), and over the treatment of physician’s choice (TH3RESA trial). A network meta-analysis suggested T-DM1 was the best treatment in terms of both overall survival and PFS compared with lapatinib in combination with capecitabine; trastuzumab in combination with capecitabine; and capecitabine monotherapy. Adverse event (AE) data were taken from a pooled analysis of additional trials of T-DM1 as a single agent. The most common grade 3 or greater AEs for T-DM1 were thrombocytopenia and hepatotoxicity. Following the clarification process, the manufacturer reported a deterministic incremental cost-effectiveness ratio (ICER) for T-DM1 compared with lapatinib in combination with capecitabine of £167,236, the latter of which was estimated to have an ICER of £49,798 compared with capecitabine monotherapy. The ERG produced similar values of £166,429 and £50,620 respectively. All other comparators were dominated. During the appraisal, the manufacturer offered an analysis of a patient access scheme (PAS), which suggested that T-DM1 had a 0 % probability of being cost-effective at an ICER of £30,000 per QALY gained. The NICE Appraisal Committee concluded that while the clinical effectiveness of T-DM1 had been proven, it was not likely to represent a cost-effective use of National Health Service resources and therefore its use could not be recommended.

Suggested Citation

  • Hazel Squires & Matt Stevenson & Emma Simpson & Rebecca Harvey & John Stevens, 2016. "Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NI," PharmacoEconomics, Springer, vol. 34(7), pages 673-680, July.
    • Handle: RePEc:spr:pharme:v:34:y:2016:i:7:d:10.1007_s40273-016-0386-z
    DOI: 10.1007/s40273-016-0386-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-016-0386-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-016-0386-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Unknown, 2014. "Department Publications 2013," Publications Lists 206935, University of Minnesota, Department of Applied Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kim Loader, 2018. "Small- and medium-sized enterprises and public procurement: A review of the UK coalition government's policies and their impact," Environment and Planning C, , vol. 36(1), pages 47-66, February.
    2. Jacopo Arpetti & Antonio Iovanella, 2019. "Towards more effective consumer steering via network analysis," Papers 1903.11469, arXiv.org, revised Nov 2019.
    3. Jeremy Greenwood & Nezih Guner & Guillaume Vandenbroucke, 2017. "Family Economics Writ Large," Journal of Economic Literature, American Economic Association, vol. 55(4), pages 1346-1434, December.
    4. Mai, Nhat Chi, 2022. "Capital Raising and Management of Vietnamese Small and Medium Sized Enterprises after Integrating into Global Economy," OSF Preprints dv68m, Center for Open Science.
    5. Kate Golebiowska, 2016. "Are Peripheral Regions Benefiting from National Policies Aimed at Attracting Skilled Migrants? Case Study of the Northern Territory of Australia," Journal of International Migration and Integration, Springer, vol. 17(3), pages 947-971, August.
    6. Namik Top & Alpaslan Sahin & Kadir Almus, 2015. "A Stimulating Experience," SAGE Open, , vol. 5(3), pages 21582440156, September.
    7. Diego Collado & Bea Cantillon & Karel Van den Bosch & Tim Goedemé & Dieter Vandelannoote, 2016. "The end of cheap talk about poverty reduction: the cost of closing the poverty gap while maintaining work incentives," ImPRovE Working Papers 16/08, Herman Deleeck Centre for Social Policy, University of Antwerp.
    8. Andrew Cleves & Paul Dimmock & Neil Hewitt & Grace Carolan-Rees, 2016. "The TURis System for Transurethral Resection of the Prostate: A NICE Medical Technology Guidance," Applied Health Economics and Health Policy, Springer, vol. 14(3), pages 267-279, June.
    9. Oliveira, Victor & Frazao, Elizabeth, 2015. "The WIC Program: Background, Trends, and Economic Issues, 2015 Edition," Economic Information Bulletin 197543, United States Department of Agriculture, Economic Research Service.
    10. Böhm, Sebastian & Grossmann, Volker & Strulik, Holger, 2021. "R&D-driven medical progress, health care costs, and the future of human longevity," The Journal of the Economics of Ageing, Elsevier, vol. 18(C).
    11. Jennifer M Bell & Michael D Shields & Ashley Agus & Kathryn Dunlop & Thomas Bourke & Frank Kee & Fiona Lynn, 2015. "Clinical and Cost-Effectiveness of Procalcitonin Test for Prodromal Meningococcal Disease–A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-16, June.
    12. Bradley T. Hiller & Peter M. Guthrie & Aled W. Jones, 2016. "Overcoming Ex-Post Development Stagnation: Interventions with Continuity and Scaling in Mind," Sustainability, MDPI, vol. 8(2), pages 1-26, February.
    13. Mehri , N. & Messkoub, M. & Kunkel, S., 2019. "Trends, determinants and the implications of population aging in Iran," ISS Working Papers - General Series 646, International Institute of Social Studies of Erasmus University Rotterdam (ISS), The Hague.
    14. Mahdi Gharaibeh & Ali McBride & David S. Alberts & Brian Erstad & Marion Slack & Nimer Alsaid & J. Lyle Bootman & Ivo Abraham, 2018. "Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer," PharmacoEconomics, Springer, vol. 36(11), pages 1333-1343, November.
    15. Shamsheer Ul Haq & Pomi Shahbaz & Azhar Abbas & Zahira Batool & Bader Alhafi Alotaibi & Abou Traore, 2022. "Tackling Food and Nutrition Insecurity among Rural Inhabitants: Role of Household-Level Strategies with a Focus on Value Addition, Diversification and Female Participation," Land, MDPI, vol. 11(2), pages 1-19, February.
    16. Paul Cheshire & Stephen Gibbons & Jemma Mouland, 2017. "Social Tenants' Health: Evaluating the Effectiveness of Landlord Interventions," SERC Discussion Papers 0219, Centre for Economic Performance, LSE.
    17. C Alexiou & J G Nellis, 2016. "A post-mortem of austerity: the Greek experience," Economic Issues Journal Articles, Economic Issues, vol. 21(2), pages 1-32, September.
    18. Wainio, John & Dyck, John & Meade, Birgit Gisela Saager & Mitchell, Lorrarine & Zahniser, Steven & Arita, Shawn & Beckman, Jayson F. & Burfisher, Mary E., 2014. "Agriculture in the Trans-Pacific Partnership," Economic Research Report 188429, United States Department of Agriculture, Economic Research Service.
    19. Nicholas Crafts, 2014. "Ireland’s Medium-Term Growth Prospects: a Phoenix Rising?," The Economic and Social Review, Economic and Social Studies, vol. 45(1), pages 87-112.
    20. Robert Koulish, 2016. "Using Risk to Assess the Legal Violence of Mandatory Detention," Laws, MDPI, vol. 5(3), pages 1-20, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:34:y:2016:i:7:d:10.1007_s40273-016-0386-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.